Shopping Cart

Your shopping cart is currently empty

TAK-901

Name: TAK-901
Brand: TargetMol
SKU: T2709
Price: 30 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T2709Cas No. 934541-31-8

Alias TAK901

TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.

TAK-901

Copy Product Info

🥰Excellent

Purity: 99.59%

Catalog No. T2709Alias TAK901Cas No. 934541-31-8

TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$30	In Stock	In Stock
5 mg	$64	In Stock	In Stock
10 mg	$106	In Stock	In Stock
25 mg	$213	In Stock	In Stock
50 mg	$347	In Stock	In Stock
100 mg	$553	In Stock	In Stock
200 mg	$788	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$72	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.59%

Appearance:Solid

Color:Yellow

Resource Download

COA HNMR LCMS

Product Introduction

TAK-901 AI Summary

TAK-901 exhibits potent bioactivity against several kinases, notably Aurora A and B. It shows a kon (association rate constant) of 629,666.67 Ms⁻¹, k_off (dissociation rate constant) of 0.008821 s⁻¹, and a Kd (dissociation constant) of 14.02 nM for AuroraA. It also has an IC50 of 21.0 nM for Aurora A/TPX2 and 15.0 nM for Aurora B/INCENP. Furthermore, it demonstrates a prolonged half-life of 15.33 hours and a high affinity constant (Ki = 0.02 nM) for Aurora B/INCENP, indicating strong inhibitory binding characteristics. In antiviral assessments, TAK-901 has been shown to inhibit SARS-CoV-2 induced cytotoxicity in both Caco-2 and VERO-6 cells at a concentration of 10 µM after 48 hours, though the inhibition percentages are marginally negative. It also significantly inhibits the SARS-CoV-2 3CL-Pro protease with a notable inhibitory effect of -217.2% at 20 µM concentration. Additionally, in enzymatic assays, TAK-901 demonstrates inhibitory activity against human HDAC6 with a commercial peptide substrate at 12.39%, whereas a slight negative inhibition (-3.8%) occurs with a custom peptide substrate..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Targets&IC50	FGR:<2.0 nM, c-Src:1.3 nM, CLK2:<2.0 nM, YES1:<2.0 nM, JAK3:1.2 nM, Aurora B:15 nM, Aurora A:21 nM
In vivo	A large set of kinase assays showed that TAK-901 inhibited multiple kinases (including FLT3, FGFR and Src family kinases) with IC50 values similar to those of Aurora A and B. TAK-901 inhibited Aurora A-TPX2 and Aurora B-INCENP in a tightly bound manner in a time-dependent manner.TAK-901 inhibited Aurora A-TPX2 and Aurora B-INCENP in a time-dependent manner. TAK-901 inhibited the NFkB and JAK/STAT pathways with submicromolar potency in a panel of pathway-specific reporter gene-based cell models.TAK-901 inhibited cell proliferation in human tumor cell lines from various tissues with IC50s ranging from 40 to 500 nM.TAK-901 inhibited the proliferation of human PC3 prostate cancer and HL60 acute myeloid leukemia cells in human PC3 prostate cancer and HL60 acute myeloid leukemia cells as determined by immunofluorescence and flow cytometry. Myeloid leukemia cells, consistent with Aurora B inhibition.TAK-901 inhibited Flt3 and FGFR2 autophosphorylation in cells with IC50 values close to those of Aurora B as measured by intracellular histidine H3 phosphorylation, whereas the IC50s for inhibition of intracellular Src and Bcr Abl were 20-fold weaker.
Synonyms	TAK901

Chemical Properties

Molecular Weight	504.64
Formula	C₂₈H₃₂N₄O₃S
Cas No.	934541-31-8
Smiles	CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12
Relative Density.	1.33 g/cm3

Storage & Solubility Information

Storage

In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 93 mg/mL (184.29 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.9816 mL	9.9081 mL	19.8161 mL	99.0805 mL
5 mM	0.3963 mL	1.9816 mL	3.9632 mL	19.8161 mL
10 mM	0.1982 mL	0.9908 mL	1.9816 mL	9.9081 mL
20 mM	0.0991 mL	0.4954 mL	0.9908 mL	4.9540 mL
50 mM	0.0396 mL	0.1982 mL	0.3963 mL	1.9816 mL
100 mM	0.0198 mL	0.0991 mL	0.1982 mL	0.9908 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc